Jefferies analyst Glen Santangelo argues that the inherent volatility of R1 RCM‘s business “has rattled investor confidence” and believes a business like RCM – with growth, attractive margins, and cash flows – “may be better off” in the near-term as a private company. With shares trading about 25% below the historical average, the analyst adds that the firm’s leveraged buyout, or LBO, analysis “suggests an acquisition could generate 20%+ IRR over a 5-year period for an acquirer” and contends that “this level of growth, cash flow, and valuation put the company on PE radar screens.” The firm maintains a Buy rating and $18 price target on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RCM:
- R1 RCM price target lowered to $20 from $26 at TD Cowen
- R1 RCM Completes Acquisition of Acclara, Providence’s Modular Services Business
- R1 RCM named ‘Top Pick in Healthcare Technology’ at Morgan Stanley
- R1 RCM reports preliminary Q4 revenue $563M-$567M, consensus $586.58M
- R1 RCM price target lowered to $13 from $18 at KeyBanc